Abstract
Estrogens are known to be an important factor in the development of estrogen-sensitive diseases. Among the enzymes involved in the biosynthesis of steroid hormones, 17β-hydroxysteroid dehydrogenase type 12 (17β-HSD12) is responsible for the reduction of estrone (E1) to estradiol (E2), this later revealed to stimulate the proliferation of estrogensensitive cells. To better understand the role of 17β-HSD12 and to better control the formation of E2 in a therapeutic perspective, we concentrated our work on synthesizing inhibitors. Knowing that a side chain at position 17α and the absence of any functional group at position 3 of E2 are important for inhibitory activity, we generated two series of 17α- amido-3-desoxyestradiol derivatives and measured their potential as inhibitors of 17β-HSD12. Parallel liquid-phase organic synthesis was used to prepare library A (36 compounds), while library B (19 compounds) was generated by direct carbonylation using high density microwave irradiation. The inhibitory results have shown that compounds from library B produced promising inhibition of 17β-HSD12, unlike compounds from library A. Indeed, seven compounds in library B inhibited the enzyme activity (transformation of E1 to E2) by 41-57% and 69-74% at 1 and 10 μM, respectively.
Keywords: 17βHydroxysteroid dehydrogenase, enzyme, inhibitor, steroid, estrone, cancer, chemical synthesis, amination, amidation, estrogens
Current Enzyme Inhibition
Title: Synthesis and Evaluation of Amido-Deoxyestradiol Derivatives as Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 12
Volume: 7 Issue: 3
Author(s): Siham Farhane, Michelle-Audrey Fournier and Donald Poirier
Affiliation:
Keywords: 17βHydroxysteroid dehydrogenase, enzyme, inhibitor, steroid, estrone, cancer, chemical synthesis, amination, amidation, estrogens
Abstract: Estrogens are known to be an important factor in the development of estrogen-sensitive diseases. Among the enzymes involved in the biosynthesis of steroid hormones, 17β-hydroxysteroid dehydrogenase type 12 (17β-HSD12) is responsible for the reduction of estrone (E1) to estradiol (E2), this later revealed to stimulate the proliferation of estrogensensitive cells. To better understand the role of 17β-HSD12 and to better control the formation of E2 in a therapeutic perspective, we concentrated our work on synthesizing inhibitors. Knowing that a side chain at position 17α and the absence of any functional group at position 3 of E2 are important for inhibitory activity, we generated two series of 17α- amido-3-desoxyestradiol derivatives and measured their potential as inhibitors of 17β-HSD12. Parallel liquid-phase organic synthesis was used to prepare library A (36 compounds), while library B (19 compounds) was generated by direct carbonylation using high density microwave irradiation. The inhibitory results have shown that compounds from library B produced promising inhibition of 17β-HSD12, unlike compounds from library A. Indeed, seven compounds in library B inhibited the enzyme activity (transformation of E1 to E2) by 41-57% and 69-74% at 1 and 10 μM, respectively.
Export Options
About this article
Cite this article as:
Farhane Siham, Fournier Michelle-Audrey and Poirier Donald, Synthesis and Evaluation of Amido-Deoxyestradiol Derivatives as Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 12, Current Enzyme Inhibition 2011; 7 (3) . https://dx.doi.org/10.2174/157340811798807614
DOI https://dx.doi.org/10.2174/157340811798807614 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evaluation of Changes in the Expression Profile of mRNA and Proteinencoding Adiponectin in Ishikawa Cell Line under the Influence of Cisplatin – Preliminary Report
Current Pharmaceutical Biotechnology Design of Combretastatin A-4 Analogs as Tubulin Targeted Vascular Disrupting Agent with Special Emphasis on Their Cis-Restricted Isomers
Current Pharmaceutical Design Cytotoxicity and Toxicity to Animals and Humans of Ribosome-Inactivating Proteins
Mini-Reviews in Medicinal Chemistry Liposomes as Versatile Platform for Cancer Theranostics: Therapy, Bio-imaging, and Toxicological Aspects
Current Pharmaceutical Design Luminescent Silica Nanoparticles for Cancer Diagnosis
Current Medicinal Chemistry A Systematic Review and Meta-Analysis about the Effect of Bisphosphonates on the Risk of Skeletal-Related Event in Men with Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Utilization of Lipid-based Nanoparticles to Improve the Therapeutic Benefits of Bortezomib
Anti-Cancer Agents in Medicinal Chemistry Significant Association of miR-605 rs2043556 with Susceptibility to Breast Cancer
MicroRNA Bilirubin and the Genome: The Hereditary Basis of Unconjugated Neonatal Hyperbilirubinemia
Current Pharmacogenomics The Molecular Mechanisms of TRAIL Resistance in Cancer Cells: Help in Designing New Drugs
Current Pharmaceutical Design Role of Chitosan Biomaterials in Drug Delivery Systems: A Patent Perspective
Recent Patents on Materials Science Practical Aspects in the Use of Biomarkers for the Development of Cancer Vaccines
Current Cancer Therapy Reviews Therapy-Related Changes in the Serum Proteome Patterns of Early Stage Breast Cancer Patients with Different Outcomes
Protein & Peptide Letters Design of Fucoidan Functionalized - Iron Oxide Nanoparticles for Biomedical Applications
Current Drug Delivery Editorial [Hot topic: Targeting Nitric Oxide for Tumor Therapy (Executive Editor: Antonio Contestabile)]
Current Pharmaceutical Design Probiotics in Curing Allergic and Inflammatory Conditions - Research Progress and Futuristic Vision
Recent Patents on Inflammation & Allergy Drug Discovery Meet Our Editorial Board Member
Current Drug Targets Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
Current Medicinal Chemistry P38 MAPK Contributes to Resistance and Invasiveness of HER2- Overexpressing Breast Cancer
Current Medicinal Chemistry The Processing of Chitosan and Its Derivatives and Their Application for Postoperative Anti-Adhesion
Mini-Reviews in Medicinal Chemistry